Sales of Padcev, a treatment for advanced bladder cancer Pfizer gained through its $43 billion deal for Seagen, also came in ahead of analysts' expectations. The Seagen deal, as well as its $4 ...

The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S. The ...

Shares of Pfizer and Viking Therapeutics have been on markedly different trajectories over the prior three years. In this comparison, Pfizer scans as a safer choice for cautious investors ...

Pfizer (NYSE: PFE) and Viking Therapeutics (NASDAQ: VKTX) perfectly embody this situation. Pfizer's shares offer a rock-bottom valuation and a sky-high dividend yield. Viking Therapeutics ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 second-quarter 2024 dividend on the company’s common stock, payable June 14 ...

Pfizer (PFE) closed at $26.26 in the latest trading session, marking a +1% move from the prior day. This move outpaced the S&P 500's daily gain of 0.87%. Elsewhere, the Dow gained 0.67%, while the ...

Pfizer (NYSE:PFE) said it has received FDA approval for its one-time gene therapy Beqvez for the treatment of certain adults with hemophilia B. The drugmaker said the therapy is aimed at enabling ...

Complaint centred around a tweet shared by medical director of company that watchdog ruled had 'limited' information Credit: MARK LENNIHAN/AP Pfizer has been accused by the UK’s pharmaceutical ...

After nearly two years of legal back and forth, Pfizer and its German partner BioNTech have won a brief reprieve in their patent fight against mRNA rival Moderna. In a docket entry dated Friday ...

Pfizer has faced numerous challenges, including a decline in COVID-19 vaccine demand and high costs, but the worst is likely priced into the stock. The company is focusing on innovation and has ...

Pfizer (NYSE: PFE) is scheduled to report its Q1 2024 results on Wednesday, May 1. We expect the company to post revenue of $13.8 billion and earnings of $0.50 on a per share and adjusted basis ...

As Pfizer races to grow the respiratory syncytial virus (RSV) vaccine market along with rival GSK, the company has been looking to expand its vaccine's reach. Now, armed with fresh data for ...